Evidence map›Paper›PMID 30568476›Full record

ArticleClinical, cosmetic and investigational dermatology2018

Treatment of facial lipoatrophy, morphological asymmetry, or debilitating scars with the hyaluronic acid dermal filler Princess

Daisy Kopera, Zrinka Ivezic-Schoenfeld, Ira G Federspiel, Doris Grablowitz, Benjamin Gehl, Martin Prinz

4 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05239117 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Plenhyage® (Polymerised Polynucleotides Dermal Filler) in the Treatment of Dermal Tissue Defects

TypeinterventionalSponsorI.R.A. Istituto Ricerche Applicate S.p.A.Ran2022 to 2022Enrolled48ConditionsCicatrix, Lipodystrophy, PlaqueArmsPlenhyage
NCT05239130 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Auralya® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial Dermal Tissue Defects

TypeinterventionalSponsorI.R.A. Istituto Ricerche Applicate S.p.A.Ran2022 to 2022Enrolled48ConditionsCicatrix, Lipodystrophy, PlaqueArmsAuralya
NCT05239156 nacompletednot on this mapstarted 2022, after this paper: background citation

Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Janesse® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial Dermal Tissue Defects

TypeinterventionalSponsorI.R.A. Istituto Ricerche Applicate S.p.A.Ran2022 to 2022Enrolled48ConditionsCicatrix, Lipodystrophy, PlaqueArmsJanesse
NCT05239351 nacompletednot on this mapstarted 2022, after this paper: background citation

Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Jalucomplex® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial and Neck Dermal Tissue Defects

TypeinterventionalSponsorI.R.A. Istituto Ricerche Applicate S.p.A.Ran2022 to 2022Enrolled48ConditionsCicatrix, Lipodystrophy, PlaqueArmsJalucomplex
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Facial Injectable Fillers in Aesthetic Medicine: Clinical Applications and Safety Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  4. Safety And Efficacy Of PrincessClinical, cosmetic and investigational dermatology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daisy KoperaDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Zrinka Ivezic-SchoenfeldCroma-Pharma GmbH, Leobendorf, Austria, martin.prinz@croma.at.
Ira G FederspielCroma-Pharma GmbH, Leobendorf, Austria, martin.prinz@croma.at.
Doris GrablowitzMedical Aesthetic Centre Vienna, Vienna, Austria.
Benjamin GehlPrivate Practice, Vienna, Austria.
Martin PrinzCroma-Pharma GmbH, Leobendorf, Austria, martin.prinz@croma.at.
Croma Pharma (Austria) · ATMedical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to evaluate the effectiveness and safety of hyaluronic acid (HA) dermal filler when used in the face for medical reconstructive purposes. PATIENTS AND

methodsAdult patients with moderately severe facial lipoatrophy (FLA), morphological asymmetry (MA) of the face, or debilitating scars (DS) on the face were included in a prospective, noncomparative, multicenter, postmarket clinical follow-up study. All patients were treated with an HA filler (Princess

resultsFifty-three patients were included in the study (FLA 23, MA 17, and DS 13), and 46 patients completed a 6-month follow-up (FLA 20, MA 15, and DS 11). At Week 4 (primary endpoint), the overall treatment success rate was 100% (FLA), 100% (MA), and 94% (DS), based on assessments made by the investigator, patients, and the independent reviewer, respectively. In most patients (~95%), the effect was sustained over 6 months. Treatment-related adverse events were reported in five patients (9%) and included injection site hematoma, injection site pain, and headache.

conclusionDermal filling with HA gel is a viable treatment option for the correction of various deformities of the face resulting from FLA, MA, or DS.

Indexed as

clinical studydermal fillereffectivenesshyaluronic acidPrincess® FILLERsafety

Identifiers

PMID30568476
PMCPMC6267730
OpenAlexW2903538623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.